ArticleFrontiers in neurology2025
Alterations in plasma cytokine profiles in generalized myasthenia gravis following different immunotherapeutic regimens.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cytokine Profiles in Myasthenia Gravis Subgroups and the Lack of Any Effect of Immunosuppression.Muscle & nerve · 2026Article
- Precision Oncology in Thymic Epithelial Tumors: Therapeutic Horizons and Implementation Barriers.International journal of molecular sciences · 2026Review
- Cytokine Changes With Effective Drug Therapy for Juvenile Myasthenia Gravis.Journal of immunology research · 2026Article
- Reference intervals for plasma IFN-α, TNF-α, IL-12p70, and IFN-γ by flow cytometry in healthy adults from eastern China: a single-center study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The pathogenesis of myasthenia gravis (MG) involves an imbalance of various pro-inflammatory and anti-inflammatory cytokines. Currently, there are no clinical studies comparing the effects of hormones and different non-hormonal immunosuppressants on the regulation of plasma cytokines. Hence, there is no unified standard for drug selection. This study aims to explore the associations between glucocorticoid (GC), tacrolimus (TAC), and rituximab (RTX) and plasma cytokine levels in generalized myasthenia gravis, providing an observational overview of how different treatment regimens relate to immune-inflammatory patterns in clinical practice. Methods: A retrospective collection of 65 GMG patients diagnosed at the Department of Neurology, General Hospital of the People's Liberation Army from July 2022 to May 2024 was conducted. According to treatment regimens, patients were divided into a GC group ( Results: Compared with the HC group, GMG patients in the NM group showed significantly higher plasma levels of IL-1β, IL-2, IL-4, IL-10, IL-17, TNF- Conclusion: Cytokine levels were markedly elevated in the plasma of patients with GMG, indicating their potential involvement in disease-related immune dysregulation. Distinct treatment groups displayed different cytokine patterns, reflecting heterogeneous immunological states among patients receiving GC, TAC, or RTX. Collectively, these findings provide preliminary immunological insights into GMG and highlight the need for validation in larger, prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.